
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
about 28 years ago
Participating Facultyabout 28 years ago
Medical Management of Epilepsy: Issues and Implicationsabout 28 years ago
Demographics and Cost of Epilepsyabout 28 years ago
Anticonvulsants: Choices and Costsabout 28 years ago
Care of Children With Epilepsyabout 28 years ago
Vagus Nerve Stimulationabout 28 years ago
Determining Costs and Cost-Effectiveness of Epilepsyabout 28 years ago
Selected Abstractsabout 28 years ago
CME Quizabout 28 years ago
Bibliography





